Impedimed Limited
IPD.ASXHealth Care
The development and sale internationally of medical devices for diagnosing and monitoring human disorders and diseases.
Market Data
$0.007
+0.2%$14.0M
-100000.0x
$-0.012
0.00%
-0.8%
Latest Earnings
Appendix 4D and Interim Financial Report
26 February 2026
ImpediMed Limited reported strong revenue growth of 25% to $7.5M for H1 FY26, driven by increased SOZO Usage Fees. However, the company continues to generate significant losses with NPAT of -$12.3M despite the improved revenue performance, and faces ongoing going concern considerations with limited cash of $18.8M. Key points: Strong revenue growth of 25% to $7.5M driven by increased SOZO Usage Fees ($7.2M vs $5.7M pcp); Gross margin remained healthy at 87% compared to 88% in prior period; Successfully drew additional US$5.0M under SWK facility following achievement of FY25 sales target
Recent Announcements
Becoming a substantial holder
Acorn Capital Limited became a substantial holder (5.64%).
Appendix 4D and Interim Financial Report
ImpediMed Limited reported strong revenue growth of 25% to $7.5M for H1 FY26, driven by increased SOZO Usage Fees. However, the company continues to generate significant losses with NPAT of -$12.3M despite the improved revenue performance, and faces ongoing going concern considerations with limited cash of $18.8M. Key points: Strong revenue growth of 25% to $7.5M driven by increased SOZO Usage Fees ($7.2M vs $5.7M pcp); Gross margin remained healthy at 87% compared to 88% in prior period; Successfully drew additional US$5.0M under SWK facility following achievement of FY25 sales target
FY26 Half Year Financial Results
ImpediMed delivered strong H1 FY26 results with revenue up 25% to $7.5M driven by expanding SOZO device install base and recurring usage fees. The company expanded into new markets with first Heart Health sale achieved and commenced weight management market entry targeting A$650M addressable market. Strong reimbursement coverage improvement to 93% US national coverage supports near-term growth prospects. Key points: Revenue growth of 25% to $7.5M with strong recurring revenue model showing 26% increase; Annual Recurring Revenue increased 15% to $14.4M with Total Contract Value up 9% to $8.7M; Significant reimbursement coverage improvement to 93% US national coverage (323M lives) from 87%
Get real-time alerts for IPD
Receive AI-powered earnings summaries and instant notifications when Impedimed Limited releases results.
Register Free